Results 171 to 180 of about 663,024 (297)

Editorial note: Theory and practices of the corporate board in the international context

, 2019
Montserrat Manzaneque Lizano
openalex   +2 more sources

International Editorial Advisory Board (1992 & 1993) [PDF]

, 1992

openalex   +1 more source

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Raising the bar: The EBOT-TK Turkish Oral Exam milestone and AOTT's commitment to orthopaedic education. [PDF]

Acta Orthop Traumatol Turc
Yalçınkaya M, Akan K, Aydıngöz Ö, Berk H, Demirhan M, Mineiro J, Gómez-Barrena E.   +6 more
europepmc   +1 more source

International editorial board/Intemasionale redaksieraad

, 1997

openalex   +1 more source

Detecting FR‐⍺ Expression Level in Cytology Effusion Specimens From Ovarian Cancer and Comparing It With Tissue Specimens

Diagnostic Cytopathology, EarlyView.
ABSTRACT Background Folate receptor‐⍺ (FR‐⍺) is an attractive target for targeted therapy. Mirvetuximab soravtansine (MIRV) has been approved by the United States Food and Drug Administration (FDA) for treating adult patients with FR‐⍺ positive, platinum‐resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Therefore,
Yadan Ma, Xiaofei Yu, Xiaohong Duan, Siqian Huang, Sishi Bai, Baizhou Li   +5 more
wiley   +1 more source

Correction: Nosi et al. MET Exon 14 Skipping: A Case Study for the Detection of Genetic Variants in Cancer Driver Genes by Deep Learning. <i>Int. J. Mol. Sci.</i> 2021, <i>22</i>, 4217. [PDF]

Int J Mol Sci
Nosi V, Luca A, Milan M, Arigoni M, Benvenuti S, Cacchiarelli D, Cesana M, Riccardo S, Di Filippo L, Cordero F, Beccuti M, Comoglio PM, Calogero RA.   +12 more
europepmc   +1 more source

Neurofeedback for Binge‐Eating Disorder: Neurophysiological Outcome Predictors and Rapid Response

International Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Pioneer studies suggested the effectiveness of food‐specific electroencephalography (EEG) and real‐time functional near‐infrared spectroscopy (rtfNIRS) neurofeedback (NF) trainings in the treatment of binge‐eating disorder (BED). These trainings aim to improve participants' neurophysiological self‐regulation.
Ben Schreglmann, Ricarda Schmidt, Michael Lührs, Anja Hilbert   +3 more
wiley   +1 more source

RETRACTION: CXCL13 Promotes Osteogenic Differentiation of Mesenchymal Stem Cells by Inhibiting miR-23a Expression. [PDF]

Stem Cells Int
International SC.
europepmc   +1 more source

The difficult discussion on the deactivation of implantable cardioverter devices at the end of life: a systematic review

ESC Heart Failure, Volume 12, Issue 2, Page 733-760, April 2025.
Abstract Implantable cardioverter defibrillators (ICDs) reliably prevent death due to life‐threatening arrhythmias; this may become less relevant in people with more severe heart failure who are reaching the end of life (EOL). This review aimed to explore the ICD deactivation process and identify ethical issues, especially around the initiation of ...
Siobhan C. Murray, Claire McNamara, Anna V. Chatzi   +2 more
wiley   +1 more source